NCT05407324 - Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | Biotech Hunter

Enrollment

249

Participants

Timeline

Start Date

November 15, 2022

Primary Completion Date

October 22, 2024

Study Completion Date

May 31, 2027

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

Dazucorilant 300 mg

300 mg of dazucorilant will be administered once daily in 4 softgel capsules of 75 mg dazucorilant/capsule.

DRUG

Dazucorilant 150 mg

Dazucorilant and placebo will be administered once daily in 4 softgel capsules, 2 capsules with 75 mg dazucorilant/capsule and 2 capsules of placebo equivalent.

OTHER

Placebo

Placebo will be administered once daily in 4 softgel capsules of placebo equivalent.

Trial Locations (35)

1307

268, Dresden

3000

108, Leuven

7747

265, Jena

10032

353, New York

13353

255, Berlin

13385

261, Marseille

18147

267, Rostock

28046

303, Madrid

29010

282, Málaga

30625

260, Hanover

30721

385, Krakow

37000

256, Tours

42395

423, Montpellier

46026

194, Valencia

53127

270, Bonn

59037

258, Lille

69500

422, Bron

75651

262, Paris

81675

386, München

85013

062, Phoenix

87042

257, Limoges

89081

269, Ulm

94109

278, San Francisco

07753

287, Neptune City

L8N 3Z5

425, Hamilton

H3A2B4

273, Montreal

06001

259, Nice

D09 YD60

253, Dublin

3584 CW

264, Utrecht

85-163

283, Bydgoszcz

01-684

254, Warsaw

02-473

274, Warsaw

08003

302, Barcelona

08035

115, Barcelona

ST4 6QG

263, Stoke-on-Trent